ITTO20040125A1 - Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica - Google Patents

Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica

Info

Publication number
ITTO20040125A1
ITTO20040125A1 IT000125A ITTO20040125A ITTO20040125A1 IT TO20040125 A1 ITTO20040125 A1 IT TO20040125A1 IT 000125 A IT000125 A IT 000125A IT TO20040125 A ITTO20040125 A IT TO20040125A IT TO20040125 A1 ITTO20040125 A1 IT TO20040125A1
Authority
IT
Italy
Prior art keywords
amidins
inhibitive
inflammatory
production
nitrogen oxide
Prior art date
Application number
IT000125A
Other languages
English (en)
Inventor
Roberto Artusi
Antonio Giordani
Francesco Makovec
Stefano Mandelli
Lucio Claudio Rovati
Ilario Verpilio
Simona Zanzoli
Original Assignee
Rotta Research Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rotta Research Lab filed Critical Rotta Research Lab
Priority to IT000125A priority Critical patent/ITTO20040125A1/it
Publication of ITTO20040125A1 publication Critical patent/ITTO20040125A1/it
Priority to PT05101498T priority patent/PT1571142E/pt
Priority to AU2005200915A priority patent/AU2005200915B2/en
Priority to CA2498644A priority patent/CA2498644C/en
Priority to ES05101498T priority patent/ES2395639T3/es
Priority to EP05101498A priority patent/EP1571142B1/en
Priority to JP2005056076A priority patent/JP4896415B2/ja
Priority to US11/068,347 priority patent/US7674809B2/en
Priority to US12/688,298 priority patent/US20100120802A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
IT000125A 2004-03-01 2004-03-01 Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica ITTO20040125A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT000125A ITTO20040125A1 (it) 2004-03-01 2004-03-01 Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica
PT05101498T PT1571142E (pt) 2004-03-01 2005-02-28 Novas amidinas heterocíclicas anti-inflamatórias e analgésicas que inibem a produção de óxido nítrico (no)
AU2005200915A AU2005200915B2 (en) 2004-03-01 2005-02-28 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
CA2498644A CA2498644C (en) 2004-03-01 2005-02-28 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (no) production
ES05101498T ES2395639T3 (es) 2004-03-01 2005-02-28 Amidinas heterocíclicas antiinflamatorias y analgésicas novedosas que inhiben la producción de óxido de nitrógeno (NO)
EP05101498A EP1571142B1 (en) 2004-03-01 2005-02-28 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
JP2005056076A JP4896415B2 (ja) 2004-03-01 2005-03-01 酸化窒素（ｎｏ）生成を抑制する新規抗炎症性および鎮痛性複素環式アミジン化合物
US11/068,347 US7674809B2 (en) 2004-03-01 2005-03-01 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
US12/688,298 US20100120802A1 (en) 2004-03-01 2010-01-15 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000125A ITTO20040125A1 (it) 2004-03-01 2004-03-01 Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica

Publications (1)

Publication Number Publication Date
ITTO20040125A1 true ITTO20040125A1 (it) 2004-06-01

Family

ID=34746743

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000125A ITTO20040125A1 (it) 2004-03-01 2004-03-01 Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica

Country Status (8)

Country Link
US (2) US7674809B2 (it)
EP (1) EP1571142B1 (it)
JP (1) JP4896415B2 (it)
AU (1) AU2005200915B2 (it)
CA (1) CA2498644C (it)
ES (1) ES2395639T3 (it)
IT (1) ITTO20040125A1 (it)
PT (1) PT1571142E (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117264222A (zh) * 2023-01-17 2023-12-22 内蒙古大学 一种咪唑基氢键有机框架室温磷光材料的制备方法及应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
CA2607219A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
ZA200809659B (en) * 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
ITMI20061368A1 (it) * 2006-07-14 2008-01-15 Acraf Composto 2-arilindolico sostituito in posizione 5, composizione farmaceutica che lo comprende nonche' composti intermedi e procedimento per prepararlo
PL2057148T3 (pl) * 2006-07-31 2010-06-30 Rottapharm Spa Amidynowe pochodne 2-heteroarylochinazolin i chinolin, silne środki przeciwbólowe i środki przeciwzapalne
US7994181B2 (en) 2006-08-03 2011-08-09 Rottapharm S.P.A. 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
WO2009062318A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
WO2009080788A2 (en) * 2007-12-21 2009-07-02 Universite Catholique De Louvain Antibacterial agents
ES2388196T3 (es) 2008-03-06 2012-10-10 Rottapharm S.P.A. Derivados de 2-aril- y 2-heteroaril-4H-1-benzopiran-4-ona-6-amidino para el tratamiento de artritis, cáncer y dolor relacionado
BRPI0822462A2 (pt) 2008-06-20 2015-10-13 Rottapharm Spa derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina.
ES2553771T3 (es) 2010-10-08 2015-12-11 Nivalis Therapeutics, Inc. Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
JP5990187B2 (ja) 2010-12-16 2016-09-07 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物
KR20160134865A (ko) * 2014-04-14 2016-11-23 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용
US20170298081A1 (en) * 2014-08-08 2017-10-19 Kasuma Partners Inc. Condensed heterocyclic compound
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
DE102021207925A1 (de) 2021-07-23 2023-01-26 Continental Reifen Deutschland Gmbh Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff
WO2023146844A1 (en) * 2022-01-25 2023-08-03 University Of Houston System Non-steroidal anti-inflammatory compounds
CN114539120A (zh) * 2022-03-09 2022-05-27 台州学院 一种吲哚类钾离子通道激动剂的制备方法
CN114957221B (zh) * 2022-05-30 2023-05-12 广西师范大学 一种喹喔啉衍生物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8603459A1 (es) * 1983-09-29 1985-12-16 Akzo Nv Un procedimiento para la preparacion de nuevos derivados de quinazolina e isoquinolina.
JPS6160648A (ja) * 1984-08-31 1986-03-28 Teikoku Hormone Mfg Co Ltd ２−（３，５−ジアルキル−４−ヒドロキシフエニル）インド−ル誘導体
EP0219307A3 (en) * 1985-10-16 1987-10-14 Merck Frosst Canada Inc. 2-substituted quinolines
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
AU699489B2 (en) * 1994-10-12 1998-12-03 Euro-Celtique S.A. Novel benzoxazoles
GB9425701D0 (en) 1994-12-20 1995-02-22 Wellcome Found Enzyme inhibitors
TW397812B (en) 1995-02-11 2000-07-11 Astra Ab Bicyclic isothiourea derivatives useful in therapy
ES2259795T3 (es) * 1995-06-07 2006-10-16 Nippon Shinyaku Company, Limited Derivados de pirrol y composicion medicinal.
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
JPH10265450A (ja) 1997-03-25 1998-10-06 Mitsui Chem Inc 一酸化窒素合成酵素阻害作用を有する新規なアミジン誘導体
IL134930A (en) * 1997-09-08 2004-06-20 Schering Ag Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
JP2003519623A (ja) * 1999-12-20 2003-06-24 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Ｄｎａ小溝結合剤としてのジアミジン化合物
WO2002030888A2 (en) * 2000-10-10 2002-04-18 Calyx Therapeutics, Inc. Tricyclic compounds and uses thereof
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2004014885A1 (en) 2002-08-07 2004-02-19 Neuraxon Inc. Amino benzothiazole compounds with nos inhibitory activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117264222A (zh) * 2023-01-17 2023-12-22 内蒙古大学 一种咪唑基氢键有机框架室温磷光材料的制备方法及应用

Also Published As

Publication number Publication date
JP2005247848A (ja) 2005-09-15
AU2005200915A1 (en) 2005-09-15
EP1571142A1 (en) 2005-09-07
PT1571142E (pt) 2012-11-20
US7674809B2 (en) 2010-03-09
JP4896415B2 (ja) 2012-03-14
CA2498644C (en) 2013-09-17
ES2395639T3 (es) 2013-02-14
EP1571142B1 (en) 2012-09-12
US20100120802A1 (en) 2010-05-13
AU2005200915B2 (en) 2011-04-14
CA2498644A1 (en) 2005-09-01
US20050197331A1 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
DE602004017108D1 (de) Stickstoff enthaltende kondensierte ringverbindung und deren verwendung als hiv-integrasehemmer
NO20050884D0 (no) Ny fremgangsmate for syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
AU2003301662A8 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
ATE430145T1 (de) 3-ä(2-ä 4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü -propionsäure- ethylester -methansulfonat und dessen verwendung als arzneimittel
IS2919B (is) Samsetning og andveiruvirkni umskiptra azaindóloxóediksýrupíperazínafleiðna
ATE370958T1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
EP1539729A4 (en) NITROSED NON-TESTED OXIDE COMPOUNDS, COMPOSITIONS, AND APPLICATION METHODS
ATE370931T1 (de) Heterozyklische verbindungen und ihre verwendungen
NO20042882L (no) Kinazolinderivater for behandling av unormal celle vekst
ATE474833T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
ATE517081T1 (de) Hydroxamsäureester und deren pharmazeutische verwendung
NO20052420D0 (no) Farmakologisk behandling av sovnapn±.
AU2002357063A1 (en) Novel topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
DE60320440D1 (de) Stickstoff-oxidierung der geätzten mos-gate-struktur
ITRM20020306A0 (it) Esteri in posizione 20 di camptotecine.
FI20020360A0 (fi) Biologisesti aktiivisen tuotteen uusi käyttö
EP1484012A4 (en) ELECTRODE STRUCTURE BODY
DE602004006815D1 (de) Monolithischer Halbleiterlaser und dessen Herstellungsverfahren
DE60238856D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ITMI20040124A1 (it) Macrolidi ad attivita' antiinfiammatoria
SE0203313L (sv) Behållare med syrabarriär och användning därav
PL371539A1 (en) Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof
EP1852432A4 (en) NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE